消风散加减联合富马酸依美斯汀滴眼液治疗过敏性结膜炎临床研究

<正>过敏性结膜炎会引起结膜充血等症状，显著降低患者的生活质量，严重者影响到角膜，导致角膜瘢痕和泛眼膜^[1]。中医药治疗过敏性结膜炎临床疗效显著^[2]。中医学认为本病归属于“时复症”“目痒症”范畴，患者外感风热邪气，郁滞睑肤肌腠，眼睑内遍生卵石状颗粒，眼痒难忍，灼热微痛，发为本病，治疗以祛风止痒为治疗原则。本研究予消风散加减联合富马酸依美斯汀滴眼液治疗过敏性结膜炎，临床效果显著，现报道如下。

Clinical observation on the treatment of allergic conjunctivitis with Xiaofengsan combined with Emestine fumarate eye drops in waigan fengre syndrome

Objective: To investigate the clinical effect of Xiaofengsan and combined with Emestine fumarate eye drops in the treatment of waigan fengre syndrome allergic conjunctivitis. Methods: 98 cases of patients with waigan fengre syndrome allergic conjunctivitis were selected from our hospital and divided into observation group and control group with 49 cases respectively according to random number table method. The control group was treated with emestine fumarate eye drops, and the observation group was treated with Xiaofengsan on the basis of control group. To observe the clinical efficacy, symptom and sign scores of allergic conjunctivitis, serum inflammatory indicators [serum hyaluronic acid (HA), eosinophilic cationic protein (ECP), interleukin-6 (IL-6)], tear film stability [tear film rupture time (BUT), corneal fluorescein staining test (FL)] and safety evaluation of 2 groups were observed before and after treatment. Results: After treatment, the observation group total effective rate was 89.79% higher than that of the control group 77.55%(P < 0.05). After treatment, the scores of symptoms and signs of allergic conjunctivitis and serum inflammatory factors were lower in the two groups than before treatment, and the observation group was lower than the control group (P < 0.05). After treatment, the tear film rupture time of both groups was higher than before treatment, and FL score was lower than before treatment, and the improvement range of observation group was better than control group (P < 0.05). Conclusion: Xiaofengsan combined with emestine fumarate eye drops in the treatment of waigan fengre syndrome allergic conjunctivitis has significant clinical effect.